| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0024-3205(97)00038-6 |
| P698 | PubMed publication ID | 9121365 |
| P50 | author | Steven A. Farber | Q54305358 |
| P2093 | author name string | R M Nitsch | |
| D M Müller | |||
| K Mendla | |||
| P2860 | cites work | Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 |
| Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
| Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors | Q24294213 | ||
| RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease | Q24314906 | ||
| beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity | Q28593175 | ||
| Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion | Q28609364 | ||
| Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment | Q29547294 | ||
| Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 | ||
| The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor | Q29618322 | ||
| Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production | Q34280406 | ||
| WAL 2014--a muscarinic agonist with preferential neuron-stimulating properties | Q34360995 | ||
| Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein | Q36364676 | ||
| beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease. | Q40384274 | ||
| Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils | Q41173971 | ||
| Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells | Q41361359 | ||
| Amyloid precursor protein secretion and beta A4 amyloid generation are not mutually exclusive | Q41450284 | ||
| Hydrogen peroxide mediates amyloid beta protein toxicity | Q41460857 | ||
| Inhibition of beta-amyloid production by activation of protein kinase C. | Q41511447 | ||
| Production of the Alzheimer amyloid beta protein by normal proteolytic processing | Q41599298 | ||
| beta-Amyloid precursor protein isoforms show correlations with neurones but not with glia of demented subjects | Q48228293 | ||
| The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth | Q48458288 | ||
| Dysfunction of cholinergic and dopaminergic neuronal systems in beta-amyloid protein--infused rats. | Q49087107 | ||
| Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. | Q53180704 | ||
| An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. | Q53207278 | ||
| Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. | Q53209417 | ||
| Regulated secretion of beta-amyloid precursor protein in rat brain | Q71511604 | ||
| Preparative methods for brain slices: a discussion | Q71519225 | ||
| Making the best of brain slices: comparing preparative methods | Q71519228 | ||
| P433 | issue | 13-14 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 985-991 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Life Sciences | Q5256275 |
| P1476 | title | Muscarinic M1 receptor agonists increase the secretion of the amyloid precursor protein ectodomain | |
| P478 | volume | 60 |
| Q40650293 | 6beta-acetoxy nortropane regulated processing of amyloid precursor protein in CHOm1 cells and rat brain |
| Q34147757 | AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease |
| Q30388923 | Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders |
| Q36269317 | Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling |
| Q34121565 | Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? |
| Q40909041 | Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission. |
| Q37130148 | Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme |
| Q28287090 | Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease |
| Q64052629 | Constipation in Tg2576 mice model for Alzheimer's disease associated with dysregulation of mechanism involving the mAChR signaling pathway and ER stress response |
| Q35538840 | M<sub>1</sub> Muscarinic Agonists Can Modulate Some of the Hallmarks in Alzheimer's Disease: Implications in Future Therapy |
| Q38192962 | M1 muscarinic acetylcholine receptor in Alzheimer's disease |
| Q43651491 | Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists |
| Q43720996 | Reduction of cortical amyloid beta levels in guinea pig brain after systemic administration of physostigmine. |
| Q34061109 | Regulation of APP cleavage by alpha-, beta- and gamma-secretases |
| Q28570077 | Simultaneous changes in secretory amyloid precursor protein and β-amyloid peptide release from rat hippocampus by activation of muscarinic receptors |
| Q34039304 | Strategies to delay the onset of Alzheimer's disease. |
| Q44416619 | Synthesis and muscarinic activities of O-[(benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. |
| Q36622649 | The significance of the cholinergic system in the brain during aging and in Alzheimer's disease |
| Q33756911 | Theoretical basis for the benefit of postmenopausal estrogen substitution |
| Q52590407 | Therapeutic potential of multifunctional tacrine analogues. |
| Q34262792 | Treatment of Alzheimer's disease with cholinesterase inhibitors |
Search more.